Rahul N. Khurana, MD
Show Description +
Rahul N. Khurana, MD, discusses the phase 3 results of the CEDAR and SEQUOIA double masked, randomized controlled clinical trials that evaluated over 1800 patients comparing abicipar pegol (Allergan) with ranibizumab (Lucentis, Genentech) for the treatment of neovascular age-related macular degeneration.
Posted: 10/29/2018
Rahul N. Khurana, MD
Rahul N. Khurana, MD, discusses the phase 3 results of the CEDAR and SEQUOIA double masked, randomized controlled clinical trials that evaluated over 1800 patients comparing abicipar pegol (Allergan) with ranibizumab (Lucentis, Genentech) for the treatment of neovascular age-related macular degeneration.
Posted: 10/29/2018
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2018.
Please log in to leave a comment.